Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Gemcitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 known ✓ | P09884 | 2/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 3/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.60 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.60 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.60 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.49 |
| ▸ | ALB | P02768 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.49 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.49 |
| ▸ | CDA | P32320 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemcitabine SCHEMBL6369622 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL366874 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL9143689 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL18389585 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL9140896 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL19235640 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL13262185 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL9140892 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL20827751 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL12737233 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173079-A1 | Conjugate Molecules | DIVERSE BIOTECH, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20220409582-A1 | COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA | SEALD AS (NO) | 2022-12-29 | — | — | US | disclosed |
| US-11219633-B2 | Nucleobase analogue derivatives and their applications | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-01-11 | — | — | US | disclosed |
| US-11040051-B2 | Formulation comprising a gemcitabine-prodrug | NuCana plc (GB) | 2021-06-22 | — | — | US | disclosed |
| WO-2021028842-A1 | A STABLE READY-TO-USE INJECTABLE COMPOSITION OF GEMCITABINE OR ITS SALT AND METHODS FOR PRODUCING SAME | HETERO HEALTHCARE LIMITED (IN) | 2021-02-18 | — | — | WO | disclosed |
| US-20200397810-A1 | FORMULATION COMPRISING A GEMCITABINE-PRODRUG | NuCana plc (GB) | 2020-12-24 | — | — | US | disclosed |
| US-20200268783-A1 | COMBINATION THERAPY FOR CANCER | NuCana plc (GB) | 2020-08-27 | — | — | US | disclosed |
| US-10660912-B2 | Combination therapy for cancer | NuCana plc (GB) | 2020-05-26 | — | — | US | disclosed |
| US-10662213-B2 | Gemcitabine prodrugs | NuCana plc (GB) | 2020-05-26 | — | — | US | disclosed |
| US-10463684-B2 | Nucleobase analogue derivatives and their applications | BOARD OF REGENTS, THE UNEVERSETY OF TEXAS SYSTEM (US) | 2019-11-05 | — | — | US | disclosed |
| US-10220051-B2 | Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer | INSTITUTE FOR CANCER RESEARCH | 2019-03-05 | — | — | US | disclosed |
| EP-2739154-B1 | VITAMIN B6 DERIVATIVES OF NUCLEOTIDES, ACYCLONUCLEOTIDES AND ACYCLONUCLEOSIDE PHOSPHONATES | MBC PHARMA INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-9944670-B2 | Gemcitabine derivatives, compositions comprising same and pharmaceutical applications thereof | Hangzhou Yuanchang Medical Sci-Tech Co., Ltd (CN) | 2018-04-17 | — | — | US | disclosed |
| US-20180064808-A1 | COMBINATION THERAPY OF BISPECIFIC ANTIBODIES SPECIFIC FOR FAP AND DR5 AND CHEMOTHERAPEUTIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20170157162-A1 | NUCLEOBASE ANALOGUE DERIVATIVES AND THEIR APPLICATIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-08 | — | — | US | disclosed |
| US-20170107246-A1 | GEMCITABINE PRODRUGS | NUCANA BIOMED LIMITED (GB) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040051-B2 | Formulation comprising a gemcitabine-prodrug | PNP, TYMP, DPYD | POLA1 821/4885PDE3A 426/4885PDE4D 460/4885 |
| US-10220051-B2 | Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer | UNG, MPG, OGG1 | POLA1 140/4885PDE3A 1664/4885PDE4D 2013/4885 |
| US-20200397810-A1 | FORMULATION COMPRISING A GEMCITABINE-PRODRUG | PNP, TYMP, DPYD | POLA1 821/4885PDE3A 426/4885PDE4D 460/4885 |
| US-10660912-B2 | Combination therapy for cancer | TYMP, PNP, NUCB2 | POLA1 173/4885PDE3A 3334/4885PDE4D 2866/4885 |
| US-20180064808-A1 | COMBINATION THERAPY OF BISPECIFIC ANTIBODIES SPECIFIC FOR FAP AND DR5 AND CHEMOTHERAPEUTIC AGENTS | FAP, TNFRSF1A, TNFRSF9 | POLA1 1953/4885PDE3A 4688/4885PDE4D 2601/4885 |
| US-10463684-B2 | Nucleobase analogue derivatives and their applications | PNLIP, NT5C2, ENPP3 | POLA1 492/4885PDE3A 752/4885PDE4D 663/4885 |
| US-11219633-B2 | Nucleobase analogue derivatives and their applications | PNLIP, NT5C2, ENPP3 | POLA1 486/4885PDE3A 775/4885PDE4D 688/4885 |
| US-20170107246-A1 | GEMCITABINE PRODRUGS | TYMP, PNP, MTAP | POLA1 593/4885PDE3A 823/4885PDE4D 545/4885 |
| US-20200268783-A1 | COMBINATION THERAPY FOR CANCER | TYMP, PNP, ENTPD5 | POLA1 245/4885PDE3A 2999/4885PDE4D 2906/4885 |
| US-20220409582-A1 | COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA | HDAC6, HDAC3, CHKA | POLA1 1009/4885PDE3A 3002/4885PDE4D 3270/4885 |
| US-10662213-B2 | Gemcitabine prodrugs | TYMP, PNP, MTAP | POLA1 593/4885PDE3A 823/4885PDE4D 545/4885 |
| US-20170157162-A1 | NUCLEOBASE ANALOGUE DERIVATIVES AND THEIR APPLICATIONS | PNLIP, NT5C2, ENPP3 | POLA1 486/4885PDE3A 775/4885PDE4D 688/4885 |
| US-20230173079-A1 | Conjugate Molecules | CNR2, CNR1, MAG | POLA1 4289/4885PDE3A 4385/4885PDE4D 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.